<DOC>
	<DOCNO>NCT02673879</DOCNO>
	<brief_summary>The Second Investigation Management Pericarditis ( IMPI-2 ) Trial compare effectiveness safety complete percutaneous pericardial drainage facilitate intrapericardial alteplase ( recombinant human tissue-type plasminogen activator ) conventional pericardiocentesis indicate 2176 patient large pericardial effusion due tuberculous non-tuberculous pericarditis . An internal pilot study 218 patient initially confirm feasibility conduct large-scale multi-centre clinical trial intrapericardial fibrinolysis patient large pericardial effusion , also provide preliminary safety data , follow dose find study intrapericardial alteplase .</brief_summary>
	<brief_title>IMPI 2 - A Trial Intrapericardial Alteplase Large Pericardial Effusion</brief_title>
	<detailed_description>Intrapericardial fibrinolytic agent use drainage tuberculous , purulent , neoplastic inflammatory pericardial effusion prevent recurrent effusion constrictive pericarditis . This use base evidence case report small trial statistical power reliably evaluate effect pericardial drainage facilitate intrapericardial fibrinolysis safety important clinical outcome . The Second Investigation Management Pericarditis ( IMPI-2 ) Trial compare effectiveness safety complete percutaneous pericardial drainage facilitate intrapericardial alteplase ( recombinant human tissue-type plasminogen activator ) conventional pericardiocentesis indicate 2176 patient large pericardial effusion due tuberculous non-tuberculous pericarditis . An internal pilot study 218 patient initially confirm feasibility conduct large-scale multi-centre clinical trial intrapericardial fibrinolysis patient large pericardial effusion , also provide preliminary safety data , follow dose find study intrapericardial alteplase . Hypothesis : We hypothesise patient large pericardial effusion randomize intrapericardial alteplase ensure complete pericardial drainage least 35 % reduction cardiac tamponade require pericardiocentesis constrictive pericarditis compare conventional pericardiocentesis indicate . Objectives : The primary objective IMPI-2 Trial : 1 . To demonstrate feasibility conduct multicentre clinical trial intrapericardial fibrinolysis patient large pericardial effusion , assess safety intrapericardial alteplase internal pilot study , 2 . To determine effectiveness intrapericardial alteplase reduce composite outcome cardiac tamponade require pericardiocentesis constrictive pericarditis patient large pericardial effusion full trial . Should internal pilot study demonstrate feasibility safety ; 218 patient rolled-over full scale IMPI-2 trial 2176 participant . The primary outcome first occurrence cardiac tamponade require pericardiocentesis constrictive pericarditis . The secondary safety endpoint safety intrapericardial fibrinolysis measure effect major bleeding , serious non-serious adverse event . The secondary efficacy outcome constrictive pericarditis , cardiac tamponade require pericardiocentesis , analyse separately , persistent recurrent pericardial effusion without cardiac tamponade , hospitalisation , death . The secondary diagnostic outcome proportion bacteriologically confirm tuberculosis organ tissue ; time diagnosis bacteriologically confirm tuberculosis day ; accuracy novel test diagnosis tuberculosis ; proportion specific diagnosis pericardial disease ; time diagnosis specific pericardial disease day . Study Design : IMPI-2 prospective randomize open blind end-point trial enroll 2176 patient large pericardial effusion 36 month 30 centre South Africa Africa . Eligible patient randomly assign receive complete pericardial drainage facilitate intrapericardial fibrinolysis conventional pericardiocentesis indicate enrollment study . Patients follow 2 week , 6 week , 12 week , month 6 , 12 enrollment . The IMPI Project Office , University Cape Town , South Africa manage coordinate study association Pericarditis Research Unit , Walter Sisulu University , South Africa Population Health Research Institute , McMaster University , Canada . Importance : IMPI-2 address serious complication large pericardial effusion ( i.e. , cardiac tamponade constrictive pericarditis ) , associate high mortality despite pericardiocentesis pericardiectomy . This study utilise research network establish IMPI trial complete 2014 .</detailed_description>
	<mesh_term>Pericardial Effusion</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . Age ≥ 18 year age ; 2 . Confirmed large pericardial effusion echocardiography ( i.e. , echo free space ≥1 cm anterior right ventricle heart diastole ) ; 3 . Willingness participate full duration trial ( i.e. , 12 month ) ; 4 . Provision write informed consent . 1 . Age &lt; 18 year ; 2 . Uraemic pericarditis ( i.e. , urea &gt; 21.4 mmol/l ) ; 3 . Thrombocytopenia ( i.e. , &lt; 100,000 platelet per µl ) ; 4 . Presence contraindication administration fibrinolytic agent ( i.e. , major haemorrhage major trauma ; coincidental stroke ; major surgery previous 5 day ; blood pressure &gt; 200/100 mmHg ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>